Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 0.00 (0.00%)
Spread: 0.50 (0.029%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,733.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET OPEN: TUI And Plus500 Both Rise Despite Profit Falls

Tue, 13th Aug 2019 08:43

(Alliance News) - Stock prices in London opened lower on Tuesday as concerns about the US-China trade war, protests in Hong Kong, and fears of a global economic slowdown continue to sap sentiment. The FTSE 100 was down 15.23 points, or 0.2%, at 7,211.49. The FTSE 250 was down 5.96 points at 18,907.04. The AIM All-Share was up 1.13 points, or 0.1%, at 875.44.The Cboe UK 100 index was down 0.4% at 12,219.61. The Cboe UK 250 was flat at 16,852.89. The Cboe UK Small Companies was flat at 10,928.12.In European equities, the CAC 40 in Paris was down 0.3% and the DAX 30 in Frankfurt down 0.4%. On the London Stock Exchange, TUI was the best blue-chip performer at the open, up 3.5% after the Anglo-German travel company reported revenue growth on strong performances by its experiences businesses in the third quarter. For the three months ended June, revenue rose 3.7% to EUR4.75 billion from EUR4.58 billion the year before. Revenue was supported by strong performances by the Destination Experiences, Holiday Experiences, and Cruises divisions. This was offset by weakness in the Western Region, Northern Region, and All Other Segments units.However, underlying earnings before interest, taxes & amortisation narrowed 46% to EUR100.9 million from EUR186.8 million a year prior. Profit performance was hurt by the Markets & Airlines unit sinking to a EUR103.9 million underlying Ebita loss from a EUR37.2 million profit the year prior. TUI said the third quarter was hurt by the grounding of the Boeing 737 MAX aircraft, 15 of which it had used within its holiday airline fleet, and it anticipates 737 MAX related costs of up to EUR300 million for the current financial year.TUI reiterated its full-year guidance for underlying Ebita to fall by up to 26% from last year."The overall picture is one which shows the benefits of a diversified business model. Its significant other income streams, most notably Holiday Experiences, Cruises and Destination Experiences have performed strongly in the year to date. in terms of the summer so far, bookings are virtually flat as compared to last year, which is some achievement given the circumstances and the outlook for the remainder of the summer is upbeat," said Interactive Investor analyst Richard Hunter. "TUI had the kitchen-sink experience earlier in the year with two profit warnings, so the fact that there are no further shocks has resulted in a warm share price reaction to these numbers," Hunter added. GlaxoSmithKline was up 1.0% after JPMorgan restarted coverage on the drugmaker with a Neutral rating. At the other end of the large cap index, Croda International was the worst performer, down 2.1% after Goldman Sachs cut the speciality chemicals company to Sell from Neutral. In the FTSE 250, Plus500 was the star performer, up 15% after the contract-for-difference provider said it has "performed well", despite reporting a steep drop in both revenue and profitability and slashing its dividend.Plus500's revenue for the six months to June fell 68% year-on-year to USD148.0 million, with pretax profit slumping 82% to USD63.9 million. Net profit fell 80% to USD51.6 million, with earnings before interest, taxes, depreciation, and amortisation down 81% to USD65.6 million.Plus500 will be returning USD0.2734 per share to shareholders for the period, an 80% reduction from the USD1.3786 paid out a year before. However, the firm also announced a share buyback worth USD50.0 million. The company said its half-year performance was in line with expectations, with the second quarter improving on the first after financial markets volatility increased. It said the second quarter was the strongest since new product regulations came into force in August 2018. At the other end of the large-cap index, Aston Martin Lagonda was the worst performer, down 6.0% after Credit Suisse downgraded the Valkyrie hypercar maker to Neutral from Outperform. The pound was quoted at USD1.2066 early Tuesday, soft against USD1.2071 at the London equities close Monday, ahead of UK jobless data at 0930 BST. Sterling hit a fresh two-year low of USD1.2014 on Monday.The UK unemployment rate is expected to remain at 3.8%."The pound will be back in focus for traders today as it tries to hold on above 1.20 against the dollar, despite the increased threat of no-deal Brexit and the turmoil that could bring. There may be a rare piece of good news today though as the labour market data is released. This has been a constant source of positive news for the economy and forecasts today suggest there could be more of the same," said OANDA analyst Craig Erlam.The Japanese Nikkei 225 index closed down 1.1% on Tuesday. In China, the Shanghai Composite closed down 0.6%, while the Hang Seng index in Hong Kong was down 1.7%. Financial markets in Japan reopened after being closed on Monday for the Mountain Day holiday.Increasing unrest in Hong Kong was hurting sentiment as protests extended into a third month, with the city's airport cancelling all flights in and out on Monday evening as thousands of demonstrators descended.In Tuesday's economic calendar, there is the US consumer price index at 1330 BST with the retail Redbook index due at 1355 BST.

More News
22 Nov 2023 09:48

LONDON BROKER RATINGS: RBC cuts HSBC; Liberum cuts Glencore

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
21 Nov 2023 11:52

GSK to begin phase 3 trials of low-carbon Ventolin inhaler in 2024

(Alliance News) - GSK PLC on Tuesday said it will begin phase 3 trials of a low carbon version of its metered dose inhaler Ventolin using a "next generation" propellant in 2024.

Read more
14 Nov 2023 17:04

LONDON MARKET CLOSE: FTSE 100 underwhelms as stocks jump after US CPI

(Alliance News) - European equities jumped in the wake of a cooler-than-expected US inflation reading, which took some sting out of a recent hawkish reassessment of the Federal Reserve interest rate outlook.

Read more
13 Nov 2023 09:47

GSK hails momelotinib opinion from European Medicines Agency committee

(Alliance News) - GSK PLC on Monday announced that a European Medicines Agency panel has given a positive opinion recommending momelotinib to treat myelofibrosis patients with anaemia.

Read more
9 Nov 2023 15:50

UK dividends calendar - next 7 days

Friday 10 November 
Bodycote PLCdividend payment date
Breedon Group PLCdividend payment date
Chesnara PLCdividend payment date
Finsbury Growth & Income Trust PLCdividend payment date
Invesco Bond Income Plus Ltddividend payment date
JPMorgan Emerging Markets Investment Trust PLCdividend payment date
Kerry Group PLCdividend payment date
Merchants Trust PLCdividend payment date
Mid Wynd International Investment Trust PLCdividend payment date
Mid Wynd International Investment Trust PLCspecial dividend payment date
Montanaro UK Smaller Cos Investment Trust PLCdividend payment date
Senior PLCdividend payment date
Spectris PLCdividend payment date
Spirax-Sarco Engineering PLCdividend payment date
Travis Perkins PLCdividend payment date
Monday 13 November 
no events scheduled 
Tuesday 14 November 
no events scheduled 
Wednesday 15 November 
Coats Group PLCdividend payment date
Ferguson PLCdividend payment date
JP Morgan Mid Cap Investment Trust PLCdividend payment date
Strategic Equity Capital PLCdividend payment date
Thursday 16 November 
abrdn Property Income Trust Ltdex-dividend payment date
Asian Energy Impact Trust PLCex-dividend payment date
Baillie Gifford Japan Trust PLCex-dividend payment date
BlackRock Greater Europe Investment Trust PLCex-dividend payment date
Bunzl PLCex-dividend payment date
Bytes Technology Group PLCex-dividend payment date
Centrica PLCdividend payment date
Coca-Cola Europacific Partners PLCex-dividend payment date
DX Group PLCex-dividend payment date
Empiric Student Property PLCex-dividend payment date
Fonix Mobile PLCex-dividend payment date
GCP Asset Backed Income Fund Ltdex-dividend payment date
GSK PLCex-dividend payment date
Hargreaves Lansdown PLCex-dividend payment date
Henderson Opportunities Trust PLCex-dividend payment date
ICG Enterprise Trust PLCex-dividend payment date
James Halstead PLCex-dividend payment date
Lancashire Holdings Ltdspecial ex-dividend payment date
Majedie Investments PLCex-dividend payment date
Marks & Spencer Group PLCex-dividend payment date
Murray Income Trust PLCex-dividend payment date
New Star Investment Trust PLCex-dividend payment date
NextEnergy Solar Fund Ltdex-dividend payment date
Octopus Renewables Infrastructure Trust PLCex-dividend payment date
Pershing Square Holdings Ltdex-dividend payment date
Personal Group Holdings PLCdividend payment date
Redrow PLCdividend payment date
Regional REIT Ltdex-dividend payment date
Schroder Oriental Income Fund Ltdex-dividend payment date
Scottish American Investment Co PLCex-dividend payment date
SCS Group PLCex-dividend payment date
Shell PLCex-dividend payment date
Supermarket Income REIT PLCdividend payment date
UK Commercial Property REIT Ltdex-dividend payment date
Unilever PLCex-dividend payment date
Wincanton PLCex-dividend payment date
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
8 Nov 2023 09:30

LONDON BROKER RATINGS: UBS downbeat on AJ Bell and Hargreaves Lansdown

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
2 Nov 2023 10:14

LONDON BROKER RATINGS: Bank of America starts Unite Group with 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and Wednesday:

Read more
1 Nov 2023 16:52

LONDON MARKET CLOSE: Stocks prosper ahead of central bank rate calls

(Alliance News) - Stocks in London took their lead from a positive start on Wall Street to close higher as investors prepare for interest rate decisions in the UK and US.

Read more
1 Nov 2023 16:35

London close: Stocks rise ahead of US Fed policy decision

(Sharecast News) - London's stock market finished in positive territory on Wednesday, with investors keeping a keen eye on the upcoming policy announcement from the US Federal Reserve.

Read more
1 Nov 2023 08:51

TOP NEWS: GSK ups guidance as boosted by Shingrix and Arexvy

(Alliance News) - GSK PLC on Wednesday hailed the performance of the world's first approved respiratory syncytial virus vaccine Arexvy, as it reported a rise in profit and revenue.

Read more
1 Nov 2023 08:50

LONDON MARKET OPEN: FTSE 100 up, FTSE 250 down as Aston Martin tumbles

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of key central bank decisions, as investors were cheered by some strong updates from large-cap listings.

Read more
1 Nov 2023 07:40

LONDON BRIEFING: GSK raises annual guidance following Arexvy launch

(Alliance News) - Stocks in London are called higher on Wednesday, with the main focal point for the day being the upcoming US interest rate decision.

Read more
1 Nov 2023 07:27

GSK hikes guidance after strong third quarter

(Sharecast News) - GSK announced a robust third quarter on Wednesday, prompting an upgrade to its full-year guidance.

Read more
30 Oct 2023 09:01

IN BRIEF: GSK says Jemperli meets endpoint in endometrial cancer trial

GSK PLC - Brentford, west London-based pharmaceutical maker - Jemperli, whose generic name is dostarlimab, meets endpoint of overall survival in phase III Ruby trial on adult patients with primary advanced or recurrent endometrial cancer. Jemperli, combined with standard-of-care chemotherapy, followed by dostarlimab, demonstrated a "statistically significant and clinically meaningful benefit" to the patients in the trial.

Read more
30 Oct 2023 07:06

GSK's Jemperli sees success in endometrial cancer trial

(Sharecast News) - GSK reported encouraging outcomes from part one of the 'RUBY' phase three trial evaluating the efficacy of 'Jemperli', or dostarlimab, with standard chemotherapy for treating adult patients with advanced or recurrent endometrial cancer on Monday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.